Navigation Links
Millennium Announces $200,000 Purchase Order From Greek Distributor

Nutrimedica, a Nutritional Distributor in Greece, to Purchase an Aggregate

of Over $200,000 of Resurgex(R) in 2008

BASKING RIDGE, N.J., April 1, 2008 /PRNewswire/ -- Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), today reports the receipt of a $200,000 one year purchase order for the international distribution of the Resurgex(R) line in Greece. Millennium received the purchase order from Nutrimedica which is headquartered in Athens, Greece. Nutrimedica has served as Millennium's International Distribution Partner into Greece for the past two years. They have committed to purchase over $200,000 of Resurgex products for distribution into Greece in 2008.

This commitment to purchase over $200,000 of Resurgex(R) products for the Greek Market supported by a year to date purchase rate further enhances news released by Millennium in January of 2008 which reported overall sales in the Greek Market has increased from $30,000 in 2006 to $50,000 in 2007. These sales will now exceed $200,000 for 2008 which adds to the further expansion of Resurgex(R) product line into the international marketplace.

Nutrimedica has already imported and distributed Resurgex(R) products to hospitals, pharmacies, and direct to patients in Greece. Nutrimedica reports that the continued use of the Resurgex product line in Greece supports and encourages their expectation that the product line will be successful in the international marketplace.

Nutrimedica has been successful in broadening the usage of the Resurgex product line beyond Oncology, into other hospital settings including Intensive Care Units and Surgery Clinics.

About Millennium:

Millennium's six marketed products form the Company's advanced line of nutritional formulas. Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(TM) sports nutrition formula, clinically proven to address the nutritional concerns of professional, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function. Millennium's most recent formula is a contribution to the long term care market. Resurgex Essential(TM) and Resurgex Essential Plus(TM) are comprehensive, calorically dense formulas that meet and succeed the nutritional requirements of the assisted living community.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC"). These statements have not been evaluated by the Food and Drug Administration. Resurgex(R), Resurgex Plus(R), Resurgex Select(R) and Surgex(TM) are not intended to diagnose, treat, cure, or prevent and disease.

SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
2. Millennium Over-Delivers on 2007 Goals and Financial Guidance
3. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
4. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
5. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
6. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
7. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
10. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
11. Life Sciences Leader Joins Millennium Board of Directors
Post Your Comments:
(Date:10/8/2015)... Celemics, a global pioneer of personalized medicine ... market with the establishment of Celemics America, Inc. ... Europe , has secured itself in the global ... sample preparation for DNA sequencing and genetic testing.  Next ... genetic testing more accurately, quickly, and cost effectively than ...
(Date:10/8/2015)... 8, 2015  The ALS Association, in partnership with ... Challenge to revolutionize communication technology solutions for people living ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative ... and the spinal cord. Eventually, people with ALS lose ... often leads to total paralysis and death within two ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS ... license agreement to develop and commercialize intellectual property rights belonging to The University ... February 2009, and affords exclusive worldwide rights to intellectual property based on use ...
(Date:10/7/2015)... Dallas-Fort Worth, Texas (PRWEB) , ... October 07, ... ... Stem Cell Institute ( ) will present a public educational seminar on ... diseases on Saturday, October 10th from 1:00 pm – 3:00 pm at the ...
Breaking Biology Technology:
... Nov. 28 On Monday, December 1, 2008, at,8:30 ... Therapeutics, Inc.,s (CTI) (Nasdaq and MTA: CTIC) management team ... Spectrum Pharmaceuticals,of Irvine, California to jointly market and develop ... Call Numbers, Monday, December 1, ...
... today that it is refocusing all projects and priorities around ... be seen as a,consequence of the negative recommendation of the ... 2008 regarding the,approval of Iclaprim in the U.S. , ... FDA advisory board,s recommendation the Arpida,board intends to put the ...
... house always looking good, without cleaning or giving it ... with paint that can maintain itself and get rid ... process for producing photo-catalytic, self-cleaning coatings has been developed ... and Research), and licensed to Haruna (S) Pte Ltd. ...
Cached Biology Technology:
(Date:9/24/2015)... YORK , Sept. 24, 2015  EyeLock LLC, ... be showcasing its award winning and latest technology in ... Anaheim, California . EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
(Date:9/10/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces that the San ... will feature the Wocket® smart wallet for the first ... Touch Of Modern is an online retailer ... its 7.2 million members. Customers are affluent, urban influencers ...
Breaking Biology News(10 mins):
... and their colleagues in Japan are conducting research that may ... necessary step if man someday hopes to build molecular machines ... Dr. Eric Blough, a member of the research ... Biological Sciences, said his group has shown how bionanomotors can ...
... Biologists have known for long that ecology, the interaction ... in forming new species and in modifying living ones. ... The environment defines a template and the process of ... template. Some specialized theory, a few ...
... plant virus lures aphids to infected plants by making the ... they quickly leave for tastier, healthier ones. In the process, ... entomologists. "The virus improves the cues that insects use to ... is already in the plant," said Mark C. Mescher, assistant ...
Cached Biology News: